Explore

Study Reveals Many Infants Diagnosed with Peanut Allergies May Not Be Allergic

Study Reveals Many Infants Diagnosed with Peanut Allergies May Not Be Allergic

New research indicates that a significant number of infants diagnosed with peanut allergies may actually be able to safely consume peanuts. An Australian study, as reported by News-Medical, found that approximately 35% of infants tested showed no reaction during a medically supervised peanut challenge. The study evaluated 1,275 infants under 18 months old, with 778 undergoing an oral food challenge. These infants had a history of reacting to peanuts and had positive allergy tests. During the challenge, medical professionals administered increasing amounts of peanut while closely monitoring for any reactions. While 35% of the infants did not react, allowing their suspected peanut allergy label to be removed, 65% did experience a reaction, and 12% developed anaphylaxis. All reactions were managed by medical teams during the supervised tests. This research highlights that standard skin and blood tests can indicate sensitivity but do not always confirm an allergic reaction upon consumption.

China's 30-Day Drug Approval Process Attracts U.S. Biotech First-in-Human Trials

China's 30-Day Drug Approval Process Attracts U.S. Biotech First-in-Human Trials

China's 30-Day Drug Approval Process Attracts U.S. Biotech First-in-Human Trials

New Study Reveals Potential Misdiagnosis of Infant Peanut Allergies, Highlighting Need for Supervised Testing

New Study Reveals Potential Misdiagnosis of Infant Peanut Allergies, Highlighting Need for Supervised Testing

A recent Australian study indicates that a significant portion of infants diagnosed with peanut allergies may not actually have them. The research, which evaluated 1,275 infants under 18 months, found that approximately 35% of those who underwent a medically supervised oral food challenge showed no allergic reaction, despite having a history of reacting to peanuts and positive allergy tests. During these challenges, doctors administered increasing amounts of peanut while closely monitoring for reactions. While 65% of the infants did experience a reaction, and 12% developed anaphylaxis, all reactions were managed by medical teams. This study underscores that standard skin and blood tests, while indicating sensitivity, do not always confirm an allergic reaction upon consumption, suggesting that many families might be imposing unnecessary dietary restrictions based on potentially inaccurate diagnoses.

Antengene Initiates Phase I ATTRACT Study for Autoimmune Disease Treatment ATG-201 in China and Australia

Antengene Initiates Phase I ATTRACT Study for Autoimmune Disease Treatment ATG-201 in China and Australia

Antengene Corporation Limited, a global biotech company, has announced that the first patient has been dosed in China for its Phase I ATTRACT study. This study evaluates ATG-201, Antengene's proprietary CD19 × CD3 bispecific T-cell engager antibody (TCE), in adult patients suffering from B cell-mediated autoimmune diseases. The study is being conducted in both China and Australia, with ATG-201 having received approval from the Human Research Ethics Committee (HREC) in Australia and completing the Clinical Trial Notification (CTN) process with the Therapeutic Goods Administration (TGA). ATG-201 is designed to precisely target and eliminate CD19-expressing B cells using steric hindrance masking technology, aiming to leverage the body's immune system for treating these diseases. The ATTRACT study, led by Professor Zhanguo Li, will assess the safety, tolerability, and preliminary efficacy of ATG-201 in two parts: Dose Escalation (Part I) and Dose Expansion (Part II).

Study Reveals Over One-Third of Infants Diagnosed with Peanut Allergy May Outgrow It, Challenging Diagnostic Accuracy

Study Reveals Over One-Third of Infants Diagnosed with Peanut Allergy May Outgrow It, Challenging Diagnostic Accuracy

A recent study indicates that more than one-third of infants initially diagnosed with peanut allergy may not actually have a persistent allergy, as they stop reacting to peanuts within months. This finding, supported by research from the Murdoch Children’s Research Institute and the National Allergy Centre of Excellence, suggests that current diagnostic methods like skin prick tests (SPT) and specific IgE (sIgE) tests, while sensitive, lack sufficient specificity. These tests can lead to overdiagnosis or misclassification, prompting unnecessary dietary restrictions and potential overtreatment. The research emphasizes the importance of supervised oral food challenges as the 'gold standard' for confirming a peanut allergy diagnosis, providing a clearer understanding of the natural history and diagnostic accuracy of peanut allergy in early childhood. Experts advise parents to consult allergists for retesting, as oral food challenges should only be conducted under strict medical supervision due to the risk of ...

UNC Researchers Receive $7 Million NIH Grant to Investigate Household Dust for Childhood Food Allergy Clues

UNC Researchers Receive $7 Million NIH Grant to Investigate Household Dust for Childhood Food Allergy Clues

Researchers at the University of North Carolina (UNC) Gillings School of Global Public Health and School of Medicine have been awarded a five-year, $7.07 million grant from the National Institutes of Health (NIH). The study, co-led by Dr. Julia Rager, Dr. Johanna Smeekens, and Dr. Timothy Moran, aims to explore how early-life environmental exposures within the home, particularly through household dust, influence a child's risk of developing food allergies. The project focuses on the 'home exposome,' which encompasses all environmental factors a child encounters, including food proteins, microbes, allergens, and chemicals. By analyzing dust samples collected from homes before birth and during the first few months of life, the team seeks to identify specific combinations of exposures that either increase or decrease the likelihood of food sensitization and allergy development. This research utilizes machine learning to process complex data from dust samples, clinical records, and microbiome data.

Coty Extends Marc Jacobs Licensing Agreement for 40 Years, Bolstering Prestige Portfolio

Coty Extends Marc Jacobs Licensing Agreement for 40 Years, Bolstering Prestige Portfolio

Coty Extends Marc Jacobs Licensing Agreement for 40 Years, Bolstering Prestige Portfolio

Rwandan President Paul Kagame Reaffirms Commitment to Deepening Cooperation with Australia

Rwandan President Paul Kagame Reaffirms Commitment to Deepening Cooperation with Australia

High Commissioner Innocent B. Muhizi of Rwanda recently presented his Letters of Credence to Her Excellency, the Honourable Ms. Sam Mostyn AC, Governor-General of the Commonwealth of Australia, in Canberra. During this official ceremony, High Commissioner Muhizi conveyed warm greetings from H.E. President Paul Kagame and the people of Rwanda. He also explicitly reaffirmed Rwanda's dedication to strengthening and deepening cooperation and ties between Rwanda and Australia. This diplomatic exchange signifies a formal step in reinforcing bilateral relations between the two nations. The Ministry of Foreign Affairs & International Cooperation, Rwanda, and the Consulate General of the Republic of Rwanda in Australia were also involved in this diplomatic initiative, highlighting a concerted effort to foster international partnerships.

Fennec Pharmaceuticals to Announce Third Quarter 2026 Financial Results

Fennec Pharmaceuticals to Announce Third Quarter 2026 Financial Results

Fennec Pharmaceuticals to Announce Third Quarter 2026 Financial Results

Newport Resident Advocates for Local Moratorium on New Gas Hookups to Combat Climate Change

Newport Resident Advocates for Local Moratorium on New Gas Hookups to Combat Climate Change

A Newport resident, W. Bart Lloyd, is advocating for a moratorium on new gas hookups in the city as a crucial first step to address climate change. Lloyd highlights that while efforts to preserve architectural heritage from rising sea levels are commendable, they primarily address the symptoms of climate change rather than its root cause: the use of fossil fuels. He points out that other countries, including Canada, Europe, Brazil, and Australia, are making significant progress in cutting their carbon footprints. In contrast, a proposal for a moratorium in Newport faced strong opposition at the city council, with one councilor suggesting its outright rejection. Lloyd notes that councilors who merely proposed studying the moratorium issue were unfairly criticized during the recent election season. He emphasizes the need for the city to stop contributing to the causes of climate change, suggesting that weaning off fossil fuels is a difficult but necessary undertaking.

Richard Norton's Death Linked to Unapproved Peptide Use, Raises Concerns Over Anti-Aging Treatments

Richard Norton's Death Linked to Unapproved Peptide Use, Raises Concerns Over Anti-Aging Treatments

Richard Norton, a renowned Australian actor, stuntman, and fight coordinator known for working with Hollywood stars including Tom Hardy, passed away at 75 in Melbourne on March 30, 2025. His death, attributed to cardiac arrest following peptide injections, is considered Australia's first such fatality. A coroner's report confirmed that complications from unapproved peptide preparations were the cause. Norton had sought treatment from Dr. Jerzy Muchnicki in March 2025 for fatigue, slow physical recovery, muscle loss, and shoulder pain after undergoing shoulder reconstructions. Dr. Muchnicki prescribed CJC-1295 and ipamorelin, two unapproved peptides that stimulate natural growth hormone and IGF-1 production. These substances are marketed for muscle growth, fat reduction, accelerated recovery, improved sleep, collagen production, and anti-aging effects, despite limited scientific evidence and a lack of long-term human safety studies. Norton reportedly signed an informed consent form detailing potential benef...

‘Musk’ Doc Gets International Release Dates After Questions About Overseas Rollout

‘Musk’ Doc Gets International Release Dates After Questions About Overseas Rollout

Universal has laid out its international rollout plans for Alex Gibey’s documentary about Elon Musk. “Musk,” which comes in at a hefty 3 hours and 45 minutes, will begin its global release via Universal Pictures International in the U.K., where it hits cinemas on Jan. 15, followed by Germany on Jan. 21, Spain on Feb. […]